Press coverage about PDL BioPharma (NASDAQ:PDLI) has trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PDL BioPharma earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.0851926264757 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of PDL BioPharma (PDLI) opened at $2.85 on Friday. The company has a market cap of $452.21, a PE ratio of 6.10 and a beta of 0.45. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.10 and a current ratio of 3.16. PDL BioPharma has a one year low of $1.93 and a one year high of $3.55.
PDL BioPharma (NASDAQ:PDLI) last released its earnings results on Thursday, November 2nd. The biotechnology company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01. The business had revenue of $62.75 million during the quarter, compared to analysts’ expectations of $61.86 million. PDL BioPharma had a net margin of 24.51% and a return on equity of 9.20%. The company’s quarterly revenue was up 17.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 earnings per share. research analysts forecast that PDL BioPharma will post 0.67 EPS for the current fiscal year.
A number of brokerages have weighed in on PDLI. ValuEngine upgraded shares of PDL BioPharma from a “hold” rating to a “buy” rating in a research report on Saturday, November 25th. Cowen reissued a “hold” rating and set a $3.00 target price on shares of PDL BioPharma in a research note on Friday, October 27th. Zacks Investment Research raised shares of PDL BioPharma from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Wednesday, August 16th. Finally, BidaskClub raised shares of PDL BioPharma from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $3.33.
WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.com-unik.info/2017/12/09/pdl-biopharma-pdli-earns-news-impact-rating-of-0-14.html.
PDL BioPharma Company Profile
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
What are top analysts saying about PDL BioPharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PDL BioPharma Inc. and related companies.